In a subgroup analysis of the SS cohort, patients showed a significant decrease in the median levels of LDH, white blood cell (WBC) count, Sézary cells, CD3+ T‐cell lymphocytes, CD4+ T‐cell lymphocytes, CD19+ B‐cell lymphocytes, soluble interleukin (IL)‐2 receptor (sIL‐2R), and sCD30+ T‐cell lymphocytes between baseline and follow‐up. Here, CD19 is linked to synovial sarcoma.